Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024954 | 0.81 | SRD5A1 (0.49) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13948754 | 0.81 | SRD5A1 (0.49) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL25831640 | 0.81 | SRD5A1 (0.49) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13319532 | 0.80 | SRD5A1 (0.46) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL27260973 | 0.78 | SRD5A1 (0.45) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13491585 | 0.78 | SRD5A1 (0.47) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13175771 | 0.78 | DRD2 (0.31) | — | |
| SCHEMBL683191 | 0.78 | ESR1 (0.50) | HTR2BSLC6A4OPRM1 | |
| SCHEMBL13487602 | 0.78 | HTR2C (0.50) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13319527 | 0.78 | SRD5A1 (0.47) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288036-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | THE UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-09-25 | — | — | US | disclosed |
| US-20100048914-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-02-25 | — | — | US | disclosed |
| US-20100048913-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-02-25 | — | — | US | disclosed |
| US-20100047338-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047338-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, HSD17B7 | SRD5A1 28/4885HTR2A 3517/4885HTR2C 1243/4885 |
| US-20100048914-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, CYP21A2 | SRD5A1 32/4885HTR2A 3447/4885HTR2C 1189/4885 |
| US-20100048913-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, HSD17B7 | SRD5A1 29/4885HTR2A 2986/4885HTR2C 982/4885 |
| US-20140288036-A1 | NOVEL C-17-HETEROARYL STEROIDAL CYP17 INHIBITORS/ANTIANDROGENS, IN VITRO BIOLOGICAL ACTIVITIES, PHARMACOKINETICS AND ANTITUMOR ACTIVITY | CYP17A1, HSD17B1, HSD17B7 | SRD5A1 28/4885HTR2A 3517/4885HTR2C 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.